
Release date: 2026-06-26 17:54:16 Article From: Lucius Laos Recommended: 127
Laos; pharmaceutical industry is relatively limited in scale, and domestic drug supply has long relied on imports of high-quality generic medicines from countries such as China and India. The pharmaceutical and medical device market in Laos is regulated by the Food and Drug Bureau. In recent years, with increased openness and favorable policies, some pharmaceutical companies have chosen to set up factories in Laos, and the countrys pharmaceutical sector has shown certain development momentum. The following are the major pharmaceutical companies currently operating in Laos.
Lucius Pharmaceuticals was established in 2020 and is located at No. 26, Thongmang Village, Xaysettha District, Vientiane, the capital of Laos. The company is a legally approved pharmaceutical manufacturer by the Lao government.
Production scale: Lucius Pharmaceuticals' factory covers an area of approximately 210,000 square meters. The company now produces over 200 generic drug varieties, covering multiple therapeutic areas. As of June 2024, Lucius Pharmaceuticals has obtained marketing approvals for 54 anticancer drugs.
Product portfolio: Lucius Pharmaceuticals focuses on antineoplastic agents as its core product line, having developed generic versions of targeted therapies including sotorasib, osimertinib, cabozantinib, larotrectinib, lorlatinib, and crizotinib. In addition, the company's products also include antihypertensive drugs such as aprocitentan.
Market presence: Lucius Pharmaceuticals has expanded its business to 12 countries, including Thailand, Indonesia, Cambodia, Vietnam, the Philippines, Singapore, Malaysia, Sri Lanka, Turkey, Japan, and China, and has established extensive partnerships.
Lao Alliance Pharmaceutical Group, founded in 2017, is a comprehensive pharmaceutical company integrating R&D, production, and sales. It occupies about 80 mu (approx. 5.3 hectares) and currently employs 243 staff. The company is one of the largest pharmaceutical enterprises in Laos and one of the three OTC drug manufacturers, holding about 27% of the Lao pharmaceutical market. Currently, the group is investing RMB 1.5 billion to build a new plant, with an expected annual output value of RMB 5 billion upon completion, which is poised to become the largest pharmaceutical factory in Southeast Asia.
The National Pharmaceutical Factory No. 2 is a state-owned pharmaceutical enterprise under the direct supervision of the Lao Ministry of Health. Established in the 1970s, it is one of the most comprehensive drug producers in Laos, with over 160 products including infusions, injections, oral tablets, oral capsules, oral syrups, ointments, and more.
In addition, Laos also has other state-owned manufacturers such as the National Pharmaceutical Factory No. 3.
Apart from the above, there are several other pharmaceutical companies in Laos, including ASEAN Food and Drug (Laos) Co., Ltd., Lao-Viet Pharmaceutical Factory, KPN Pharmaceutical Co., Ltd., and Lao Element Pharmaceutical, among others. These enterprises have all obtained official drug marketing approvals, and some of them specialize in the production of generic anticancer drugs.
Overall, the pharmaceutical industry in Laos remains in a developing stage, with a limited number of factories. However, companies like Lucius Pharmaceuticals are gradually expanding both domestic and international markets, driving the industry forward.
Company Overview: Industrial Migration from India to LaosLucius Pharmaceuticals (Laos) Co., Ltd. was established in 2020, with its headquarters located at No. 26, Thongmang Village···【more】
Recommended:39Release date: 2026-07-20
Lucius Pharmaceutical is one of the representative generic drug enterprises in Laos. The company was established in Vientiane, the capital of Laos, in 2020 and has been in operatio···【more】
Recommended:60Release date: 2026-07-17
Industrial Rise: From Zero to a "World Pharmacy" CandidateThe explosive growth of Laos' generic drug industry is rooted in unique international rule dividends. As a U···【more】
Recommended:76Release date: 2026-07-16
In recent years, Laos generic drugs have gradually come into view of oncology and chronic disease patients in China due to their significant price advantage. Leveraging the WTO pat···【more】
Recommended:81Release date: 2026-07-15
Regulatory System: From "One Ministry, One Department" to Legal AmendmentsLao drug regulation adopts a centralized "one ministry, one department" management mod···【more】
Recommended:89Release date: 2026-07-14
Overview of Lao generic drug industryThe Lao generic drug industry started late but has developed rapidly in recent years. Relying on the WTO's patent waiver for least develope···【more】
Recommended:92Release date: 2026-07-09
Laos's pharmaceutical industry started late and remains relatively small in scale; for a long time, domestic drug supply has relied on imports from China, India, and other coun···【more】
Recommended:100Release date: 2026-07-08
Before 2020, there were only a handful of legally approved local pharmaceutical manufacturers in Laos, mostly small state-owned factories with outdated equipment. Within just a few···【more】
Recommended:111Release date: 2026-07-07
With generic drugs as its core, Laos' pharmaceutical industry has formed an industrial pattern featuring coordination between state-owned and private enterprises as well as loc···【more】
Recommended:127Release date: 2026-07-02
The pharmaceutical industry in Laos started late and is limited in scale, with domestic drug supply long relying on imports of quality generic medicines from China, India and other···【more】
Recommended:1116Release date: 2026-07-01
Lucius Pharmaceuticals (Lao) Co., Ltd is a Lao pharmaceutical company established in 2020, headquartered in Vientiane, the capital of Laos. Despite its short history, the company h···【more】
Recommended:154Release date: 2026-06-30
The Lao generic pharmaceutical industry has developed rapidly in recent years, attracting increasing attention from patients worldwide. As one of the least developed countries in S···【more】
Recommended:440Release date: 2026-06-29
Dr. Louis, a microbiologist at the World Health Organization (WHO), recently made a technical visit to Lucius Pharmaceuticals in Laos. The purpose of the visit was to learn more ab···【more】
Recommended:798Release date: 2024-07-09
Lung cancer is the most rapidly increasing malignant tumor with the fastest increasing morbidity and mortality, which has been troubling medical workers. Clinical studies have foun···【more】
Recommended:756Release date: 2024-07-09
Lucius version of Dacomitinib is now availableCutaneous adverse reactions and management strategies for DacomitinibRash and exfoliative skin reactions are highly characteristic adv···【more】
Recommended:19Release date: 2026-07-21
Lao PDR: Filgotinib Has Been LaunchedBefore initiating filgotinib treatment, strict screening for the following contraindications is mandatory; the presence of any one of these con···【more】
Recommended:74Release date: 2026-07-13
Lucius Pharmaceuticals' Pirtobrutinib Has Been LaunchedPirtobrutinib is an oral anticancer drug whose active ingredient is pirtobrutinib, belonging to the class of Bruton's···【more】
Recommended:97Release date: 2026-07-10
Lucius Pharmaceuticals (Lao) Co., Ltd. has launched a generic version of elagolix sodium (trade name LuciElag) for the treatment of moderate to severe pain associated with endometr···【more】
Recommended:94Release date: 2026-07-06
Contraindications for Bempedoic Acid (Nilemdo)Bempedoic acid (Nilemdo) is strictly contraindicated in the following situations: ①hypersensitivity to bempedoic acid or any excipient···【more】
Recommended:109Release date: 2026-07-03
MONDAY, June 15, 2026 — A study published online June 8 in Nature Medicine has found that apitegromab, through its selective inhibition of myostatin, can maintain lean body mass wh···【more】
Recommended:140Release date: 2026-06-24
On May 28, 2026, AstraZeneca announced that its immunotherapy drug Imfinzi (durvalumab) in combination with BCG (Bacillus Calmette-Guérin) induction and maintenance regimen has rec···【more】
Recommended:255Release date: 2026-06-01
On November 21, 2025, the U.S. Food and Drug Administration (FDA) approved the regimen of pembrolizumab (Keytruda, Merck & Co., Inc.) or pembrolizumab and berahyaluronidase alf···【more】
Recommended:573Release date: 2025-12-17
On December 12, 2025, the U.S. Food and Drug Administration (FDA) approved niraparib in combination with abiraterone acetate (brand name: Akeega, Janssen Biotech, Inc.) plus predni···【more】
Recommended:518Release date: 2025-12-15
The U.S. Food and Drug Administration (FDA) announced today that it has approved Omisirge (omidubicel-onlv), the first hematopoietic stem cell transplantation (HSCT) therapy for th···【more】
Recommended:547Release date: 2025-12-10
On December 4, 2025, the U.S. Food and Drug Administration (FDA) approved lisocabtagene maraleucel (Breyanzi, developed by Juno Therapeutics, a subsidiary of Bristol Myers Squibb) ···【more】
Recommended:524Release date: 2025-12-08
On December 3, 2025, the U.S. Food and Drug Administration (FDA) granted full approval to pirtobrutinib (Jaypirca, Eli Lilly and Company) for the treatment of adult patients with r···【more】
Recommended:600Release date: 2025-12-04

Lucius Pharmaceutical Co., Ltd., was established in 2020 in Vientiane, the capital of Laos. It aims to offer safe, effective, and affordable medicines globally. With a factory spanning 25,000 square meters, the company manufactures 200+ generic drugs in diverse therapeutic fields.
Address: No.26 Thongmang village, Xaythany district, Vientiane Capital, Laos
E-mail:laoslucius@gmail.com

Name: Lucius

Telegram name: Vira
No.:0085253923643
Telegram name: Vira
No.:0085253923643